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1. Background
Although somatic mutations in the Janus kinase
2 gene (JAK2) occur in many Philadelphia-
chromosome negative chronic myeloproliferati-
ve neoplasms (PN-MPNs), disease evolution,
distinct phenotypes and the continuous clinical
evidence of an increasing number of cases, with
younger patients affected, have been pointing to
a growing involvement of environmental factors
in the pathogenesis of these diseases. Although
this association is well established in some
solid tumors, like breast and thyroid, this aspect
We intend to evaluate the role of apoptosis SNPs in PN-MPNs susceptibility.
2. Objectives
Our results do not reveal a significant involvement of apoptosis polymorphisms on the
individually susceptibility towards PN-MPNs.
However, larger studies are required to confirm these results and to provide conclusive evidence
of non association between these and other apoptosis variants and PN-MPNs and therapeutic
response.
On the other hand, there are studies that show modifications in the expression of molecules that
participate in the regulation of apoptosis, indicating that this mechanism is involved in the
pathophysiology of these diseases.
Identification of the main molecules that are altered in MPNs allows the development of drugs
more directly targeted to the pathophysiology of the disease, with high efficacy, fewer adverse
effects, contributing to compliance of the patients with treatments.
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We performed a case-control study in 121 Caucasian Portuguese PN-MPNs patients (73 with Essential
thrombocythaemia (ET), 35 with Polycythaemia vera (PV) and 13 with Primary Myelofibrosis (PMF)) and 280
matched controls. Most of the patients were diagnosed and are followed by some of the elements of this
working group. rs2227309 and rs2227310 (CASP7), rs1045485 and rs1035142 (CASP8), rs2308950, rs1820204
and rs1052571 (CASP9) and rs13006529 (CASP10) were genotyped using real-time PCR (RT-PCR 7300 Applied
Biosystem), through TaqMan® SNP genotyping assays (Life Technology), according to manufacturer instructions.
Differences in genotype frequency, smoking status, age class, gender, therapeutic and pathology distributions
between patients and controls were evaluated using SPSS 22.0 (SPSS Inc.).
3. Methods
None of the apoptosis polymorphisms studied, individually considered, is associated with PN-
MPNs risk.
No significant difference was found between the case and control groups concerning age
distribution, gender, smoking habits or genotype frequencies (Table 1). No significant change in
crude or adjusted OR was observed for any of the genotypes considered (Table 2).
Studies related with therapeutic response are still ongoing.
4. Results
Characteristics Cases, n (%) Controls, n (%) P value
Gender
Male
Female
55 (45.8)
65 (54.2)
132 (47.1)
148 (52.9)
0.8
Age a, b
30-49
50-69
≥70
16 (13.2)
47 (38.8)
58 (47.9)
43 (15.4)
106 (37.9)
131 (46.8)
0.9
Smoking habits
Never
Current
93 (76.9)
28 (23.1)
212 (76.0)
67 (24.0)
0.9
CASP7 (Arg249Lys)
Arg/Arg
Lys/Arg
Lys/Lys
70 (57.9)
45 (37.2)
6 (5.0)
153 (55.0)
109 (39.2)
16 (5.8)
0.9
CASP7 (Asp255Glu)
Asp/Asp
Asp/Glu
Glu/Glu
7 (5.8)
47 (39.2)
66 (55.0)
16 (5,8)
106 (38.5)
153 (55.6)
1.0
CASP8 (Asp302His)
Asp/Asp
Asp/His
His/His
91 (75.8)
24 (20.0)
5 (4.2)
219 (78.8)
51 (18.3)
8 (2.9)
0.7
CASP8 (Tyr12STOP)
Tyr/Tyr
Tyr/Stop
Stop/Stop
20 (16.5)
53 (43.8)
48 (39.7)
45 (16.2)
136 (48.9)
97 (34.9)
0.6
CASP9 (Phe136Leu)
Phe/Phe
Phe/Leu
Leu/Leu
28 (23.1)
66 (54.5)
27 (22.3)
87 (31.3)
128 (46.0)
63 (22.7)
0.2
CASP9 (Arg173His
Arg/Arg
Arg/His
Arg/His
117 (96.7)
3 (2.5)
1 (0.8)
275 (98.9)
3 (1.1)
0 (0.0)
0.2
CASP9 (Val762Ala)
Val/Val
Val/Ala
Ala/Ala
24 (19.8)
66 (54.5)
31 (25.6)
69 (24.8)
129 (46.4)
80 (28.8)
0.3
CASP10 (Ile522Leu)
Ile/Ile
Ile/Leu
Leu/Leu
27 (22.3)
58 (47.9)
36 (29.8)
74 (26.6)
122 (43.9)
82 (29.5)
0.6
a Age of diagnosis for cases
b Age of control population at the time of diagnosis for the matched case
Table 1 – General characteristics for the PN-MPNs cases 
(n=121) and control population (n=280).
Table 2 – ORs (95% CI) for apoptosis polymorphisms and PN-
MPNs association.
Fig. 1 – Megakaryocytes in primary myelofibrosis, bone
marrow aspirate smear (x100). 
n
OR crude
(95% CI)
OR adjusted (95% 
CI)a
CASP7 (Arg249Lys)
Arg/Arg
Arg/Lys
Lys/Lys
121
1 (Reference)
0.9 (0.6-1.4)
0.8 (0.3-2.2)
1 (Reference)
0.9 (0.6-1.4)
0.9 (0.3-2.6)
CASP7 (Asp255Glu)
Asp/Asp
Asp/Glu
Glu/Glu
120
1 (Reference)
1.0 (0.7-1.6)
1.0 (0.4-2.6)
1 (Reference)
1.0 (0.6-1.6)
1.1 (0.4-2.9)
CASP8 (Asp302His)
Asp/Aspb
Asp/His
His/His
120
1 (Reference)
1.1 (0.7-2.0)
1.5 (0.5-4.7)
1 (Reference)
1.1 (0.6-1.9)
1.3 (0.4-4.3)
CASP8 (Tyr12STOP)
Tyr/Tyr
Tyr/Stop
Stop/Stop
121
1 (Reference)
0.8 (0.5-1.3)
0.9 (0.5-1.7)
1 (Reference)
0.8 (0.5-1.3)
1.0 (0.5-1.9)
CASP9 (Phe136Leu)
Leu/Leu
Leu/Phe
Phe/Phe
121
1 (Reference)
1.6 (1.0-2.7)
1.3 (0.7-2.5) 
1 (Reference)
1.6 (1.0-2.8)
1.4 (0.7-2.6)
CASP9 (Arg173His
Arg/Arg
Arg/His + His/His
117
1 (Reference)
3.1 (0,7-14.2)
1 (Reference)
2.4 (0.5-11.0)
CASP9 (Val762Ala)
Val/Val
Val/Ala
Ala/Ala
121
1 (Reference)
1.3 (0.8-2.2)
0.9 (0.5-1.7)
1 (Reference)
1.3 (0.8-2.2)
0.9 (0.5-1.7)
CASP10 (Ile522Leu)
Ile/Ile
Ile/Leu
Leu/Leu
121
1 (Reference)
1.1 (0.7-1.8)
0.8 (0.5-1.5)
1 (Reference)
1.1 (0.6-1.8)
0.8 (0.5-1.6)
a ORs were adjusted for age (30-49, 50-69 and  ≥70), smoking status (never and 
current)
b Reference class
is now being considered for some solid tumors,
like breast and thyroid, this aspect is now being considered for hematological malignancies.
Exposure to hazardous agents in the environment on a continual basis, can lead to changes at the
genome level, alterations in cell cycle regulation and consequently to cancer. Several single
nucleotide polymorphisms (SNPs) have been identified, that may influence the DNA repair
capacity and apoptotic status, that, in turn, confer genetic predisposition to disease and
determine therapeutic response.
Expression deregulation of pro and anti-apoptotic genes promotes cell resistance to apoptosis,
culminating with the accumulation of myeloid cells and establishing neoplasms (Fig.1).
